Management of infections in critically ill neutropenic cancer patients

Journal of Critical Care

Volumn 19, Issue 3, 2004, Pages 165-173

  Buchheidt, Dieter ^a   Hummel, Margit ^a   Engelich, Georg ^a   Hehlmann, Rüdiger ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AZLOCILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; HEMOPOIETIC GROWTH FACTOR; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

CANCER SURVIVAL; FEBRILE NEUTROPENIA; GRANULOCYTE; HUMAN; INFECTION; INTENSIVE CARE; NEUTROPENIA; QUALITY OF LIFE; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 4644254893     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2004.07.007     Document Type: Article

References (76)

1. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century A period analysis. Lancet. 360:2002;1131-1135
2. Hiddemann W., Maschmeyer G., Link H., et al. Therapy of infections in patients with acute leukemia. Med Klin. 92:1997;406-409
3. Buchheidt D., Böhme A., Cornely O., et al. Diagnosis and treatment of documented infections in neutropenic patients - Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 82:(suppl 2):2003;127-132
4. Massion P.B., Dive A.M., Doyen C., et al. Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med. 30:2002;2260-2270
5. Kish M.A. Guide to development of practice guidelines. Clin Infect Dis. 32:2001;851-854
6. Einsele H., Bertz H., Beyer J., et al. Infectious complications after allogeneic stem cell transplantation Epidemiology and interventional therapy strategies - Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 82:(suppl 2):2003;175-185
7. Bodey G.P., Buckley M., Sathe Y.S., et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 64:1966;328-340
8. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. Clin Infect Dis. 34:2002;730-751
9. Link H., Blumenstengel K., Böhme A., et al. Antimicrobial therapy for fever of unknown origin in neutropenia. Dtsch Med Wochenschr. 124:1999;S3-S8
10. Klastersky J., Paesmans M., Rubenstein E.B., et al. The Multinational Association for Supportive Care in Cancer risk index A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 18:2000;3038-3051
11. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med JID-0355501. 20:1992;864-874
12. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 29:2003;530-538
13. Maschmeyer G. Interventional antimicrobial therapy in febrile neutropenic patients. Diagn Microbiol Infect Dis. 34:1999;205-212
14. Lehrnbecher T., Venzon D., de Haas M., et al. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 29:1999;414-419
15. Engel A., Mack E., Kern P., et al. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection. 26:1998;213-221
16. Engel A., Steinbach G., Kern P., et al. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever comparison with interleukin-8. Scand J Infect Dis. 31:1999;185-189
17. Kern W.V., Heiss M., Steinbach G. Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum Targeting empirical monotherapy versus combination therapy. Clin Infect Dis. 32:2001;832-835
18. Ostermann H., Rothenburger M., Mesters R.M., et al. Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol. 88:1994;332-337
19. Mesters R.M., Helterbrand J., Utterback B.G., et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med. 28:2000;2209-2216
20. Mesters R.M., Mannucci P.M., Coppola R., et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood. 88:1996;881-886
21. Maschmeyer G. Pneumonia in febrile neutropenic patients radiologic diagnosis. Curr Opin Oncol. 13:2001;229-235
22. Heussel C.P., Kauczor H.U., Heussel G.E., et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients Use of high-resolution computed tomography. J Clin Oncol. 17:1999;796-805
23. Heussel C.P., Kauczor H.U., Heussel G., et al. Early detection of pneumonia in febrile neutropenic patients Use of thin-section CT. AJR Am J Roentgenol. 169:1997;1347-1353
24. Gruson D., Hilbert G., Vargas F., et al. Usefulness of computed tomography for early detection of pneumonia in leukopenic patients. Intensive Care Med. 27:2001;444
25. Caillot D., Mannone L., Cuisenier B., et al. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect. 7:(suppl 2):2001;54-61
26. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 19:2001;253-259
27. Caillot D., Casasnovas O., Bernard A., et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 15:1997;139-147
28. Maschmeyer G., Beinert T., Buchheidt D., et al. Diagnosis and therapy of lung infiltrates in febrile neutropenic patients. Dtsch Med Wochenschr. 124:1999;S18-S23
29. Gruson D., Hilbert G., Valentino R., et al. Utility of fiberoptic bronchoscopy in neutropenic patients admitted to the intensive care unit with pulmonary infiltrates. Crit Care Med. 28:2000;2224-2230
30. Gorschlüter M., Marklein G., Hofling K., et al. Abdominal infections in patients with acute leukaemia a prospective study applying ultrasonography and microbiology. Br J Haematol. 117:2002;351-358
31. Gomez L., Martino R., Rolston K.V. Neutropenic enterocolitis spectrum of the disease and comparison of definite and possible cases. Clin Infect Dis. 27:1998;695-699
32. Picardi M., Selleri C., Camera A., et al. Early detection by ultrasound scan of severe post-chemotherapy gut complications in patients with acute leukemia. Haematologica. 84:1999;222-225
33. Mermel L.A., Farr B.M., Sherertz R.J., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 32:2001;1249-1272
34. Fätkenheuer G., Cornely O., Seifert H. Clinical management of catheter-related infections. Clin Microbiol Infect. 8:2002;545-550
35. Pinel C., Fricker-Hidalgo H., Lebeau B., et al. Detection of Circulating Aspergillus fumigatus Galactomannan Value and Limits of the Platelia Test for Diagnosing Invasive Aspergillosis. J Clin Microbiol. 41:2003;2184-2186
36. Bodey G.P. Infection in cancer patients A continuing association. Am J Med. 81:1986;11-26
37. Link H., Maschmeyer G., Meyer P., et al. Interventional antimicrobial therapy in febrile neutropenic patients Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol. 69:1994;231-243
38. Maschmeyer G., Link H., Hiddemann W., et al. Pulmonary infiltrations in febrile patients with neutropenia Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer. 73:1994;2296-2304
39. Tamura K., Matsuoka H., Tsukada J., et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides comparative study. Am J Hematol. 71:2002;248-255
40. Cometta A., Zinner S., de Bock R., et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 39:1995;445-452
41. Cometta A., Calandra T., Gaya H., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother. 40:1996;1108-1115
42. Cony-Makhoul P., Brossard G., Marit G., et al. Prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br J Haematol. 76:(suppl 2):1990;35-40
43. Maschmeyer G., Hiddemann W., Link H., et al. Management of infections during intensive treatment of hematologic malignancies. Ann Hematol. 75:1997;9-16
44. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 346:2002;225-234
45. Boogaerts M., Winston D.J., Bow E.J., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy A randomized, controlled trial. Ann Intern Med. 135:2001;412-422
46. Böhme A., Karthaus M., Einsele H., et al. Diagnosis of systemic fungal infections in hematology. Dtsch Med Wochenschr. 124:(suppl 1):1999;S24-S30
47. Maschmeyer G. New antifungal agents-treatment standards are beginning to grow old. J Antimicrob Chemother. 49:2002;239-241
48. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 347:2002;408-415
49. Maschmeyer G., Hertenstein B., Glass B., et al. Interventional antimicrobial therapy for febrile complications after high-dose chemotherapy and autologous stem cell transplantation. Dtsch Med Wochenschr. 124:(suppl 1):1999;S9-13
50. Bouchama A., Khan B., Djazmati W., et al. Hematopoietic colony-stimulating factors for neutropenic patients in the ICU. Intensive Care Med. 25:1999;1003-1005
51. Serke S. Hematopoietic growth factors as an adjunct for neutropenic patients in the ICU still a controversial issue. Intensive Care Med. 25:1999;901-902
52. Gruson D., Hilbert G., Vargas F., et al. Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients. Crit Care Med. 28:2000;3155-3160
53. Ozer H., Armitage J.O., Bennett C.L., et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors evidence-based, clinical practice guidelines: American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 18:2000;3558-3585
54. Dignani M.C., Anaissie E.J., Hester J.P., et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions a pilot study. Leukemia. 11:1997;1621-1630
55. Hubel K., Dale D.C., Engert A., et al. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis. 183:2001;321-328
56. Lee J.J., Chung I.J., Park M.R., et al. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia. 15:2001;203-207
57. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709
58. Hilbert G., Gruson D., Vargas F., et al. Noninvasive continuous positive airway pressure in neutropenic patients with acute respiratory failure requiring intensive care unit admission. Crit Care Med. 28:2000;3185-3190
59. Hilbert G., Gruson D., Vargas F., et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med. 344:2001;481-487
60. Azoulay E., Alberti C., Bornstain C., et al. Improved survival in cancer patients requiring mechanical ventilatory support impact of noninvasive mechanical ventilatory support. Crit Care Med. 29:2001;519-525
61. Kress J.P., Christenson J., Pohlman A.S., et al. Outcomes of critically ill cancer patients in a university hospital setting. Am J Respir Crit Care Med. 160:1999;1957-1961
62. Shorr A.F., Moores L.K., Edenfield W.J., et al. Mechanical ventilation in hematopoietic stem cell transplantation can We effectively predict outcomes? Chest. 116:1999;1012-1018
63. Tremblay L.N., Hyland R.H., Schouten B.D., et al. Survival of acute myelogenous leukemia patients requiring intubation/ventilatory support. Clin Invest Med. 18:1995;19-24
64. Ewig S., Torres A., Riquelme R., et al. Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU. Eur Respir J. 12:1998;116-122
65. Groeger J.S., White P. Jr, Nierman D.M., et al. Outcome for cancer patients requiring mechanical ventilation. J Clin Oncol. 17:1999;991-997
66. Brunet F., Lanore J.J., Dhainaut J.F., et al. Is intensive care justified for patients with haematological malignancies? Intensive Care Med. 16:1990;291-297
67. Groeger J.S., Aurora R.N. Intensive care, mechanical ventilation, dialysis, and cardiopulmonary resuscitation Implications for the patient with cancer. Crit Care Clin. 17:2001;791-803
68. Darmon M., Azoulay E., Alberti C., et al. Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med. 28:2002;1775-1780
69. Blot F., Cordonnier C., Buzin A., et al. Severity of illness scores are they useful in febrile neutropenic adult patients in hematology wards? A prospective multicenter study. Crit Care Med. 29:2001;2125-2131
70. Blot F., Guiguet M., Nitenberg G., et al. Prognostic factors for neutropenic patients in an intensive care unit respective roles of underlying malignancies and acute organ failures. Eur J Cancer. 33:1997;1031-1037
71. Guiguet M., Blot F., Escudier B., et al. Severity-of-illness scores for neutropenic cancer patients in an intensive care unit: Which is the best predictor? Do multiple assessment times improve the predictive value? Crit Care Med. 26:1998;488-493
72. Azoulay E., Moreau D., Alberti C., et al. Predictors of short-term mortality in critically ill patients with solid malignancies. Intensive Care Med. 26:2000;1817-1823
73. Sculier J.P., Paesmans M., Markiewicz E., et al. Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med. 28:2000;2786-2792
74. Staudinger T., Stoiser B., Mullner M., et al. Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med. 28:2000;1322-1328
75. Maschmeyer G., Bertschat F.L., Moesta K.T., et al. Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. Eur J Cancer. 39:2003;783-792
76. Boussat S., El'rini T., Dubiez A., et al. Predictive factors of death in primary lung cancer patients on admission to the intensive care unit. Intensive Care Med. 26:2000;1811-1816